GILD34:BVMF
Gilead Sciences Inc BDR
64,82 BRL
0,00%
(0,00) 1D
19 tet, 4:56:00 m.d., GMT-3 · BRL
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për GILD34...
Hap
65,69 BRL
I lartë
65,69 BRL
I ulët
64,82 BRL
Kapitalizimi i tregut
189,80 mld
Vëllimi mesatar
319,00
Vëllimi
2,00
Maksimumi 52-javor
67,38 BRL
Minimumi 52-javor
51,33 BRL
Aksionet në qarkullim
1,24 mld
Numri i punonjësve
17 mijë
Hap
65,69 BRL
I lartë
65,69 BRL
I ulët
64,82 BRL
Kapitalizimi i tregut
189,80 mld
Vëllimi mesatar
319,00
Vëllimi
2,00
Maksimumi 52-javor
67,38 BRL
Minimumi 52-javor
51,33 BRL
Aksionet në qarkullim
1,24 mld
Numri i punonjësve
17 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
MarketWatch
·
7 orë më parë
Gilead Sciences Inc. stock underperforms Monday when compared to competitors
Financial-News.co.uk
·
8 orë më parë
Gilead’s UC Pill Hits Trial Goal, Stock Still Slips
Trefis
·
12 orë më parë
What Has Changed About Owning Gilead Stock?
ad-hoc-news.de
·
13 orë më parë
Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
Profili
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Rreth Gilead Sciences Inc BDR
Drejtori ekzekutivDaniel O'Day
Punonjësit17 mijë
Themeluar më22 qer 1987
SeliaFoster City, Kalifornia, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtigilead.com